AB1112 DESCRIPTION OF THE REAL-WORLD TREATMENT PATTERNS OF GUSELKUMAB IN THE MANAGEMENT OF PSORIATIC ARTHRITIS IN AUSTRALIA: AN ANALYSIS FROM THE OPAL DATASET
Authors: G. Littlejohn, N. Anbumurali, P. Bird, P. Youssef, C. Osullivan, T. Smith, D. Sumpton, B. Kane, A. Mcgeachie, S. Spiers, C. Deakin
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Guselkumab (GUS) is a novel anti-interleukin 23 (IL-23)p19 antibody that acts as a selective and specific inhibitor of the IL-23 cytokine. GUS has been shown to significantly improve signs and symptoms of active psoriatic arthritis (PsA) and became available for the treatment of PsA in Australia in July 2021. Limited data from large real-world patient populations exist to describe the utilisation of GUS for the management of PsA. <h3>Objectives</h3> To describe the patient demographics and treatment patterns of GUS in a large real-world cohort of Australian adult patients with PsA. <h3>Methods</h3> The OPAL dataset is a collection of deidentified clinical data derived from the electronic medical records of 112 rheumatologists at 43 sites around Australia. Adult patients with a diagnosis of PsA who received at least one prescription of GUS or a biologic or targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD) between Jul 2021 and Jul 2022, were eligible for inclusion in the analysis. Results were summarised descriptively. <h3>Results</h3> A total of 1,868 patients with PsA, (GUS n=355, TNFi n=795, IL-17Ai n=371 and JAKi n=347) were eligible for inclusion in this study. The median [IQR] age of patients was 55 [44-63] years, and 70.1% were female. At baseline, median disease duration was 5[2-8], 2[1-6], 3[1-7] and 5[3-8] years, for patients treated with GUS, TNFi, IL-17Ai and JAKi, respectively. 17.7% of patients receiving GUS were first line compared with 58.7% of TNFi, 39.4% of IL-17Ai and 19.3% of JAKi treated patients (Table 1). At index, the majority of patients were treated as monotherapy. <h3>Conclusion</h3> These are the first data describing the demographics and treatment patterns of real-world Australian patients with PsA treated with GUS. In this preliminary analysis, a higher proportion of GUS and JAKi were used in later lines of therapy, and patients who initiated GUS or JAKi had a longer median disease duration. This may be due to the different time periods of availability of the different b/tsDMARD, as both GUS and JAKi are newer treatment options for PsA compared with TNFi and IL17Ai. Persistence among patients with PsA treated with GUS is currently being investigated. <h3>Acknowledgements</h3> The authors acknowledge the members of OPAL Rheumatology Ltd and their patients for providing clinical data for this study, and Software4Specialists Pty Ltd for providing the Audit4 platform. This study was conducted with financial support provided by Janssen Australia. <h3>Disclosure of Interests</h3> Geoff Littlejohn: None declared, Nithila Anbumurali: None declared, Paul Bird Speakers bureau: GSK, AbbVie, Janssen, Eli-Lilly, Consultant of: AbbVie, Janssen, Pfizer, Eli-Lilly, GSK, BMS, Peter Youssef: None declared, Catherine OSullivan: None declared, Tegan Smith: None declared, Daniel Sumpton: None declared, Barry Kane: None declared, Andrew McGeachie Employee of: Current employee of Janssen Australia, Stefanie Spiers Employee of: Current employee of Janssen Australia, Claire Deakin: None declared.